Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 2/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | RHOC | P08134 | 1/20 | 0.37 |
| ▸ | RHOA | P61586 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282669 | 0.90 | CXCR3 (0.43) | ACP1CXCR3NAMPTHCRTR1HCRTR2 | |
| SCHEMBL4276917 | 0.82 | CACNA1I (0.56) | KCNH2CACNA1I | |
| SCHEMBL4274878 | 0.81 | CXCR3 (0.45) | ACP1CXCR3NAMPTRHOCRHOA | |
| SCHEMBL19112799 | 0.80 | CXCR3 (0.42) | ACP1CXCR3NAMPTHCRTR1HCRTR2 | |
| SCHEMBL19112564 | 0.80 | CXCR3 (0.41) | CXCR3NAMPTHCRTR1HCRTR2RHOC | |
| SCHEMBL4271123 | 0.78 | CACNA1I (0.57) | KCNH2CACNA1I | |
| SCHEMBL4271321 | 0.75 | CXCR3 (0.43) | ACP1CXCR3NAMPTRHOCRHOA | |
| SCHEMBL15353982 | 0.74 | CXCR3 (0.39) | ACP1CXCR3NAMPTRHOCRHOA | |
| SCHEMBL4277786 | 0.73 | MEN1 (0.47) | ACP1CXCR3NAMPTRHOCRHOA | |
| SCHEMBL4280629 | 0.73 | CXCR3 (0.45) | ACP1CXCR3NAMPTHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189839-B1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | PRAXIS PREC MEDICINES INC (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3189839-B1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | PRAXIS PREC MEDICINES INC (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-2300007-B1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TARO PHARMACEUTICALS INC (CA) | 2018-04-18 | — | — | EP | disclosed |
| EP-2300007-B1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TARO PHARMACEUTICALS INC (CA) | 2018-04-18 | — | — | EP | disclosed |
| EP-3189839-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Taro Pharmaceuticals Inc. (CA) | 2017-07-12 | — | — | EP | disclosed |
| EP-3189839-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Taro Pharmaceuticals Inc. (CA) | 2017-07-12 | — | — | EP | disclosed |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS, LTD. (CA) | 2016-06-23 | — | — | US | disclosed |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS, LTD. (CA) | 2016-06-23 | — | — | US | disclosed |
| US-9096522-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096522-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-8569344-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-8569344-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
| US-8377968-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2013-02-19 | — | — | US | disclosed |
| US-8377968-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2013-02-19 | — | — | US | disclosed |
| US-8377968-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2013-02-19 | — | — | US | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | ACP1 2953/4885CXCR3 3807/4885NAMPT 1401/4885 |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | ACP1 2953/4885CXCR3 3807/4885NAMPT 1401/4885 |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | ACP1 2953/4885CXCR3 3807/4885NAMPT 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.